Cite
HARVARD Citation
Lombardi, G. et al. (n.d.). OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>. Neuro-oncology. p. iii219. [Online].